The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
DAXXIFY (Revance Australia Pty Ltd)
Product name
DAXXIFY
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
162 (255 working days)
Active ingredients
daxibotulinumtoxinA
Registration type
NCE/ NBE
Indication
DAXXIFY is indicated for:
- the temporary improvement in the appearance of moderate to severe glabellar linesassociated with corrugator and/or procerus muscle activity in adult patients.
- the treatment of cervical dystonia in adult patients.